Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CYCC
- Price
- 5.11
- Stock movement up
- +10.20 (9.29%)
- Company name
- Cyclacel Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 268.68M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -59.02%
- 3 year return
- -73.78%
- 5 year return
- -62.49%
- 10 year return
- -57.05%
Last updated: 2025-09-12
DIVIDENDS
CYCC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 107.25 |
| Daily high | 124.20 |
| Daily low | 107.25 |
| Daily Volume | 6K |
| All-time high | 459043200.00 |
| 1y analyst estimate | 1.00 |
| Beta | 0.09 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | 29 Apr 2025 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CYCC | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.46% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 21 Aug 2025 | 9 Mar 2009 |
| Avg drop from high | -96.00% | -10.99% |
| Avg time to new high | 1075 days | 12 days |
| Max time to new high | 5371 days | 1805 days |
COMPANY DETAILS
Marketcap
268.68M
Marketcap category
Small-cap
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Spiro Rombotis
Country
USA
City
Berkeley Heights
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner